Compare FVCB & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FVCB | ELDN |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.0M | 291.8M |
| IPO Year | 2018 | 2014 |
| Metric | FVCB | ELDN |
|---|---|---|
| Price | $17.52 | $2.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $19.38 | $9.00 |
| AVG Volume (30 Days) | 55.9K | ★ 758.2K |
| Earning Date | 10-27-2026 | 11-13-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 47.56 | 30.67 |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $1,781,000.00 | N/A |
| Revenue This Year | $19.14 | N/A |
| Revenue Next Year | $9.11 | N/A |
| P/E Ratio | $21.64 | ★ N/A |
| Revenue Growth | ★ 13.87 | N/A |
| 52 Week Low | $11.83 | $1.35 |
| 52 Week High | $19.11 | $4.60 |
| Indicator | FVCB | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 25.06 |
| Support Level | $17.28 | $1.96 |
| Resistance Level | $18.01 | $2.30 |
| Average True Range (ATR) | 0.34 | 0.13 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 52.69 | 6.00 |
FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.